Identification of a biomarker to predict doxorubicin/cisplatin chemotherapy efficacy for osteosarcoma patients by 4D data-independent acquisition (DIA) mass spectrometry with parallel reaction monitoring (PRM) verification

We analyzed the differentially expressed proteins in 37 resected tissue samples from osteosarcoma patients using paraffin- embedded specimens and 4D data-independent acquisition (DIA) quantitative mass spectrometry to investigate biomarkers for predicting the efficacy of doxorubicin/cisplatin chemotherapy